Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ABVC BioPharma, Inc. ABVC
$0.83
+$0.05 (6.40%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
29041547.00000000
-
week52high
2.90
-
week52low
0.50
-
Revenue
969783
-
P/E TTM
-5
-
Beta
0.39446300
-
EPS
-0.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Hold | Buy | 16 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Stolz Kevin Patrick | A | 6250 | 6250 | 27 янв 2012 г. |
| Krotine Frank Thomas | A | 300000 | 300000 | 25 мая 2011 г. |
| Crockett Robert G | A | 1800000 | 1800000 | 11 мая 2011 г. |
| Ramsey Sally Judith | A | 2100000 | 2100000 | 11 мая 2011 г. |
| Stolz Kevin Patrick | A | 50000 | 50000 | 11 мая 2011 г. |
| IANNOTTI DANIEL V | A | 300000 | 300000 | 11 мая 2011 г. |
| Juliano James | A | 100000 | 100000 | 12 авг 2010 г. |
| Nirta Joseph | A | 10000 | 10000 | 11 мая 2010 г. |
| IANNOTTI DANIEL V | A | 220000 | 220000 | 23 мар 2010 г. |
| Nirta Joseph | A | 2000 | 2000 | 22 мар 2010 г. |
Новостная лента
How to Find Cheap Penny Stocks to Make Money Trading
PennyStocks
06 янв 2023 г. в 06:00
Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Hot Penny Stocks Exploding After News This Week
PennyStocks
05 янв 2023 г. в 09:39
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
GlobeNewsWire
23 мар 2022 г. в 09:25
Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the company will be participating at the Maxim Group 2022 Virtual Growth Conference, taking place March 28-30, 2022.
ABVC Biopharma Stock (ABVC): Why The Price Increased
Pulse2
12 дек 2021 г. в 20:55
The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by 5.14% in the previous trading session. This is why it happened.
Why ABVC BioPharma Shares Are Trading Higher On Friday?
Benzinga
10 дек 2021 г. в 13:38
ABVC BioPharma Inc (NASDAQ: ABVC) shares gained during the market trading session on continued momentum from yesterday's dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research. Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms.